Jim Simons Gracell Biotechnologies Inc. Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$2.43 - $10.04 $17,739 - $73,292	-7,300 Reduced 15.67%	39,300 $395,000
Q3 2023 Nov 14, 2023	SELL	$2.83 - $4.9 $7,075 - $12,250	-2,500 Reduced 5.09%	46,600 $134,000
Q2 2023 Aug 11, 2023	BUY	$1.45 - $6.07 $290 - $1,214	200 Added 0.41%	49,100 $187,000
Q1 2023 May 12, 2023	SELL	$1.8 - $2.5 $180 - $250	-100 Reduced 0.2%	48,900 $91,000
Q4 2022 Feb 13, 2023	SELL	$2.08 - $3.96 $2,704 - $5,148	-1,300 Reduced 2.58%	49,000 $113,000
Q3 2022 Nov 14, 2022	BUY	$2.08 - $5.15 $832 - $2,060	400 Added 0.8%	50,300 $162,000
Q2 2022 Aug 12, 2022	BUY	$1.95 - $5.5 $51,285 - $144,650	26,300 Added 111.44%	49,900 $274,000
Q1 2022 May 13, 2022	BUY	$1.83 - $5.52 $43,188 - $130,271	23,600 New	23,600 $55,000

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.